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Clinical review
Fortnightly review
Prophylaxis of venous thromboembolism
M Verstraete
The incidence of deep vein thrombosis has for years
been underrated because it is difficult to diagnose
accurately by clinical history and physical examination.
Minimal leg symptoms may be associated with
extensive venous thrombosis whereas classic symp›
toms and signs of pain, tenderness, and swelling of the
leg can be caused by non›thrombotic disorders. In
patients without symptoms and signs of deep vein
thrombosis, the diagnosis is most often revealed by a
pulmonary embolism; indeed, less than 20% of
patients with proved pulmonary embolism have
clinical features compatible with venous thrombosis in
the legs.1 Thromboembolism in lower venous systems
usually occurs as a complication of major surgery or of
a serious illness. Without antithrombotic prophylaxis
objective diagnostic measures have shown that 8›15%
of patients develop venous thrombosis after major
general (including abdominal) surgery, 36›60% after
surgery for hip fracture, 47›57% after total hip replace›
ment, and 40›80% after total knee replacement.2
The frequency of deep vein thrombosis is less well
documented in medical patients. A recent study using
colour Doppler imaging detected an unexpectedly
high rate of deep vein thrombosis of 33% in patients in
an intensive medical care unit; 48% of these cases were
proximal leg thromboses.3 The prevalence of deep vein
thrombosis will probably increase in future because the
average age of the population and the number of can›
cer patients is increasing, high age is becoming a lesser
contraindication for major surgery, and many surgical
patients, young and old, are being discharged from
hospital before they are fully ambulant.
Thrombosis of deep leg veins is serious because
proximal vein thrombosis is the cause of fatal
pulmonary embolism in about 2 in 1000 postoperative
patients each year. Most patients who die from pulmo›
nary embolism do so within 30 minutes of the acute
event, often too soon to make a correct diagnosis
(because of the non›specificity of symptoms and signs)
or start treatment. The only way to prevent fatal and
non›fatal pulmonary embolism effectively is to prevent
proximal vein thrombosis, particularly in patients in
hospital, where the risk of fatal pulmonary embolism
can increase up to 5%, for instance in patients at high
thrombotic risk.2 Deep vein thrombosis is also
important because it can cause serious morbidity from
chronic venous insufficiency. About 50›60% of patients
with symptomatic proximal vein thrombosis and 30%
with symptomatic calf vein thrombosis develop the
post›phlebitic syndrome five to seven years later. As
there is no satisfactory treatment for this late
complication, prevention is the only approach
medicine can offer.
Methods
This review of prophylaxis against deep vein
thromboembolism is largely based on guidelines pub›
lished by the Scottish Intercollegiate Guidelines
Network and the Royal College of Physicians in
Edinburgh.4 Other recent reviews were published by
the British Society of Haematology,5 the THRIFT con›
sensus group,6 the European consensus group,7 Pineo
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Summary points
• Deep vein thrombosis is difficult to diagnose clinically
and its frequency has therefore been underestimated
• The only effective treatment is prevention, and
prophylaxis should be offered to all patients at risk
• Antithrombotic drugs are not appropriate for low risk
patients; prevention should focus on elasticated stockings
• In medium risk patients mechanical methods should
be combined with drug treatment
• In high risk patients the most effective drugs are low
molecular weight heparins
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and Hull,8 and Clagett et al.2 Throughout the review I
have used the definition of the type of evidence and the
grading of recommendations described by Cook et al.9
Effective prevention
There are two strategies for effective prevention. Firstly,
to institute primary prevention in all patients with a
medium or high risk for deep vein thrombosis, and,
secondly, to opt for secondary prevention by screening
patients with a medium or a high probability of deep
vein thrombosis with objective diagnostic tests. The
second approach is expensive, time consuming, and
can be applied to only a limited number of patients.
Moreover, impedance plethysmography and duplex
ultrasonography were shown to have only moderate
sensitivity and positive predictive value in asympto›
matic high risk patients.10 Broad application of effective
methods of prevention was shown to be more cost
effective than selective, intensive surveillance.11
Several risk factors for deep vein thrombosis have
been identified (box 1), and these can be used to distin›
guish groups of hospital patients with low, moderate, or
high thrombotic risk (box 2).
Hospital patients at low risk
The general consensus is that patients at low
thrombotic risk should not be exposed to the hazard
and costs of routine prophylaxis with presently
available antithrombotic drugs. As well as early ambu›
lation the patients should wear graduated compression
stockings, although their effectiveness is not based on
evidence from medical trials.
Hospital patients at medium risk
Graduated elastic compression stockings and inter›
mittent pneumatic compression devices are effective
after surgery, but it is unknown whether they
significantly reduce fatal pulmonary embolism. Their
effectiveness has not been evaluated in medical
patients. There is insufficient evidence that the
simultaneous use of both mechanical methods further
reduces the frequency of venous thrombosis in this
risk group. Elastic stockings should not be used on
patients with severe leg ischaemia. Mechanical
methods should, in principle, be combined with
antithrombotic drugs. These include subcutaneous
low dose unfractionated heparin (5000 IU, 12 hourly,
with 5000 IU two hours before surgery), subcutaneous
low molecular weight heparin or heparinoid (doses as
indicated in table 1), or adjusted dose warfarin (inter›
national normalised ratio 2.0›2.5).
The various brands of low molecular weight
heparins have different molecular weight distribution
profiles, specific activities (anti›Xa to anti›IIa activities),
and rates of plasma clearance, and each brand should
therefore be considered as distinct and the doses set
accordingly.12 13 Indeed, antithrombotic potencies and
potential bleeding effects of different low molecular
weight heparins cannot be extrapolated from one
product to another on the basis of weights in mg.
Box 1—Risk factors for venous thromboembolism5 7
Background factors
Age > 40 years
Severe obesity
Immobility (bed rest > 4 days)
Pregnancy
Puerperium
High dose oestrogens
Previous deep vein thrombosis or
pulmonary embolism
Thrombophilia:
Deficiency of antithrombin III,
protein C, protein S
Activated protein C resistance
Phospholipid antibody or lupus
anticoagulant
Homocystinaemia
Disease or surgical procedure
Trauma or surgery, especially of
pelvis, hip, and lower limb
Malignancy, especially pelvic or
abdominal metastatic
Heart failure
Recent myocardial infarction
Paralysis of lower limb(s)
Severe infection
Inflammatory bowel disease
Nephrotic syndrome
Polycythaemia
Paraproteinaemia
Behçet’s disease
Paroxysmal nocturnal
haemoglobinuria
Table 1 Recommended doses of commercial low molecular weight heparins in
prevention of deep vein thrombosis
Generic name
General surgery and other
conditions of moderate
thrombotic risk (anti›Xa IU)
Orthopaedic surgery and other conditions of
high thrombotic risk (anti›Xa IU)
Ardeparin — 50/kg twice daily
Certoparin 3000 once daily subcutaneously 3000 once daily subcutaneously
Dalteparin 2500 once daily 5000 once daily subcutaneously
Enoxaparin 2000 (20 mg) once daily
subcutaneously
4000 (40 mg) once daily or 3000 twice daily
subcutaneously
Nadroparin calcium 3075 once daily subcutaneously 60/kg once daily subcutaneously
Parnaparin 3200 once daily subcutaneously 6400 once daily subcutaneously
Reviparin 2500 units once daily
subcutaneously
5000 units once or twice daily
subcutaneously
Tinzaparin 3500 once daily subcutaneously 50/kg once daily subcutaneously
Danaparoid 750 twice daily subcutaneously 750 twice daily subcutaneously
Box 2—Classification of risk of deep
vein thrombosis and pulmonary
embolism for hospital patients
• Low risk (proximal vein thrombosis 0.4%, fatal
pulmonary embolism < 0.2%):
Patients < 40 years undergoing major surgery
( > 30 minutes) with no other risk factors
Patients undergoing minor surgery ( > 30 minutes)
with no other risk factors
Patients with minor trauma or illness with no
thrombophilia but history of deep vein thrombosis
or previous pulmonary embolism
• Medium risk (proximal vein thrombosis 2›4%, fatal
pulmonary embolism 0.2›0.5%):
Major general, urological, gynaecological,
cardiothoracic, vascular, or neurological surgery in
patients > 40 years or with one or more other risk
factors
Major acute medical illness such as myocardial
infarction, heart failure, chest infection, cancer, or
inflammatory bowel disease
Major trauma
Minor surgery, trauma, or illness in patients with
previous deep vein thrombosis, pulmonary
embolism, or thrombophilia
Plastercast immobilisation of the leg in patients with
minor injury
• High risk (proximal vein thrombosis 10›20%, fatal
pulmonary embolism 1›5%):
Fracture or major orthopaedic surgery of pelvis, hip,
or leg
Major pelvic or abdominal surgery for cancer
Major surgery, trauma, or illness in patients with
previous deep vein thrombosis, pulmonary
embolism, or thrombophilia
Leg paralysis
Critical leg ischaemia or major leg amputation
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These prophylactic recommendations are based on
evidence from randomised trials with low false positive
and false negative errors (grade A) for surgical patients
and those in heart failure and chest infection. The sup›
portive evidence for other patients at medium
thrombotic risk is less rigorous (grade C), being based
only on non›randomised concurrent cohort studies.9
Deep vein thrombosis is common after plastercast
immobilisation for traumatic injury. In a randomised
study the incidence of phlebographic deep vein
thrombosis was significantly less in patients treated
with one daily subcutaneous injection of a low molecu›
lar weight heparin (0%) compared with the untreated
control group (4.3%).14
When anticoagulants are contraindicated—for
example, in patients with a suspected or documented
intracranial bleeding or in those who have sustained
cerebral or spinal trauma— prophylaxis is limited to
graduated elastic compression stockings or intermit›
tent pneumatic compression. These should be used
continuously until the patient is ambulant.
Hospital patients at high risk
Grade A randomised controlled trials have shown
three methods to be effective in patients having hip
surgery: adjusted dose subcutaneous unfractionated
heparin (dosing to the upper limit of the normal
range of the activated partial thromboplastin time);
subcutaneous low molecular weight heparin or hepa›
rinoid (table 1), and adjusted moderate dose warfarin
(initial dose the evening before surgery, postoperative
international normalised ratio 2.0›3.0). Only low
molecular weight heparins, intermittent pneumatic
compression ,and adjusted dose warfarin were shown
to be effective after knee surgery. All of these methods
can be combined with graduated elastic stockings.
Intravenous dextran, a branched polysaccharide
with a molecular weight of 40 000 or 70 000, has also
been shown to be effective after major orthopaedic
surgery. However, the use of dextran is cumbersome,
expensive, and associated with rare anaphylactic
responses, and it is contraindicated in patients with
renal insufficiency and limited cardiac reserve.
Eriksson et al showed that recombinant hirudin
(desirudin), started preoperatively, was more effective
than unfractionated heparin after total hip
replacement,15 and this drug is undergoing further
clinical evaluation. Bivalirudin (hirulog) was also found
in a dose finding study to be more effective than
unfractionated heparin after hip surgery.16 In patients
who have had major hip or knee surgery low molecu›
lar weight heparins were significantly more effective
than unfractionated heparin (5000 U subcutaneously
two or three times a day).17 18 Low molecular weight
heparins were also more effective than adjusted dose
unfractionated heparin,19 oral anticoagulants,20 21 dex›
tran, 22 23 and aspirin in such patients.
Patients having major pelvic or abdominal surgery
for malignancy and those having any major surgery
who have thrombophilia or a history of deep vein
thrombosis should be given the same prophylaxis as
recommended for those having major orthopaedic
surgery. Grade A trials have also shown subcutaneous
low dose unfractionated heparin (5000 IU, 8›hourly) to
be effective in these patients.
In patients who have had a stroke and other high
risk medical patients low molecular weight heparin
reduces the risk of venous thrombosis by 60›90%.24›26
Low molecular weight heparins are also more effective
than unfractionated heparin in preventing deep vein
thrombosis in patients with spinal cord injury .27
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Science, medicine, and the future
Molecular genetic approaches to understanding disease
John Savill
Abstract
Molecular genetics has greatly increased the
understanding of diseases in which there is a single
gene defect such as cystic fibrosis. Discovering the
gene responsible and its function not only helps
determine the pathogenesis of the disease but also
offers a possible treatment—gene therapy. Polygenic
disorders such as diabetes may soon yield their secrets
to the same approach. Animal models of genetic
diseases are proving useful research tools, and
transgenesis has made xenografting possible.
Furthermore, antisense technology allows specific
inhibition of undesirably overexpressed genes such as
those driving unwanted vascular cell proliferation and
restenosis after angioplasty. The completion of the
human genome project should make the search for
“disease” genes much quicker and will increase still
further the importance of these gene based
approaches toward diseases.
Introduction
If you think that splicing is a carpentry technique or
that a knockout is the end of a politically incorrect
sporting contest you should read on. Indeed, even if
you are one of the many doctors who knows that it is
now routine to identify genes and manipulate their
expression, the hazier details may be clarified by this
article. My aim is to set out important genetic
approaches toward understanding disease and intro›
duce how advances in biomedical science may affect
medicine in the next 15 years or so. Genetic terms are
explained in the glossary. In my next article I will cover
cellular approaches. The objective of subsequent
articles in this series will be to foresee how modern sci›
ence will impinge on the prevention, diagnosis, and
treatment of common disease processes such as
coronary heart disease, hypertension, and lung cancer.
Molecular genetics
Modern molecular techniques have revolutionised
attempts to understand the pathogenesis of single gene
disorders such as cystic fibrosis. The discovery of abnor›
mal alleles seems almost routine, and the potential
rewards of “finding the gene” are great. In cystic fibrosis
the transmembrane conductance regulator (CFTR) is
inactivated by various mutations. Discovering the gene
gave an insight into pathogenesis—it was quickly
realised that CFTR is an epithelial cell surface chloride
transporter, which explains known defects in ion trans›
port across epithelia in patients with cystic fibrosis. Sec›
ondly, there was a ready made candidate treatment—
transfer to diseased tissue of the complementary DNA
(cDNA) of the normal CFTR gene which can then be
used by the cells to produce normal protein (see below)
and reconstitute chloride transport.
Molecular geneticists have made remarkable
contributions to the understanding of single gene dis›
orders. Some studies have taken the candidate gene
approach—scientists make an educated guess that a
well characterised allele lies at or close to a disease
locus. More usually, investigators undertake painstak›
ing linkage analysis of DNA specimens from affected
families. They seek to associate carefully documented
cases of disease with particular chromosomal “land›
marks” and then aim to find the gene in a relatively
short segment of DNA. This positional cloning
approach has been greatly facilitated by a comprehen›
sive map of microsatellites—regions of DNA that vary
greatly in their sequence between individuals but
which occupy identical chromosomal positions.
Once a gene is mapped to a particular section of
DNA various strategies can be used to speed the hunt
for the gene among the millions of nucleotide bases in
non›coding “junk” DNA, which constitutes up to 90%
of the human genome. For example, help may come
from the growing map of expressed sequence tags, a
library of partially sequenced cDNAs obtained from
unselected mRNAs. Furthermore, large chunks of
chromosomal DNA can be handily stored, manipu›
lated, and screened by being incorporated into a
library of yeast artificial chromosomes that contain
overlapping segments of human DNA—so called
contigs (fig 1). However, positional cloning may still be
difficult. It took years to find PKD1, the gene responsi›
ble for most cases of autosomal dominant polycystic
kidney disease, because it was hidden in a cluster of
similar genes on chromosome 16. Such difficulties may
be removed by the mapping of the human genome.
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Bolstered by success with uncommon single gene
disorders, molecular geneticists are turning to major
causes of ill health and premature death such as
coronary heart disease, hypertension, and diabetes
mellitus. These disorders cluster in families but exhibit
polygenic inheritance, expression of the disease
phenotype apparently depending on the interaction of
several genes, which may in turn interact with environ›
mental factors. Genome screening is now feasible
thanks to automated techniques and microsatellite
markers, but such linkage studies require careful
interpretation. One aim of linkage studies is to help
determine pathogenesis by identifying gene products
involved in disease. However, we will need a strong
ethical framework with which to handle the knowledge
that a particular gene is associated with increased risk
of a serious disorder. Telling someone glibly that they
have a fivefold increased risk of early death from
coronary heart disease may not be ideal.
Gene transfer and gene therapy
Gene transfer is a simple and attractive concept (fig 2).
All you need to do is take a piece of DNA that encodes
for the desired protein and transfer it to a cell. The cell
then transcribes the gene and translates the resulting
mRNA to generate protein. It is easy to appreciate why
gene transfer is causing so much excitement. Firstly,
transferring human genes to simple organisms or cell
lines allows production of large amounts of “therapeu›
tic” proteins such as erythropoietin. Secondly, there is
enthusiasm for using gene transfer to patients to treat
disease—so called gene therapy. For example, it is
hoped that normal epithelial function and defence
against infection may be restored in the airways of
patients with cystic fibrosis by transferring the normal
CFTR gene.
However, behind the simple concept lies a large
and incomplete body of knowledge. A functioning
gene is not merely composed of the encoding DNA
sequence (fig 3). Upstream of the site at which gene
transcription is initiated there is a promoter region of
DNA sequences that bind nuclear proteins called tran›
scription factors. These factors regulate the initiation
of transcription. Indeed successful elongation and
processing of a gene transcript may require coordi›
nated action of many pieces of genomic DNA which
are not expressed in the final mRNA transcript. There›
fore, although a cDNA can be “read” to generate a full
length mRNA and protein, gene transfer will not work
unless the cDNA is combined with elements designed
to drive transcription. These are usually provided by
incorporating the cDNA into a vector—a piece of DNA
which is derived from a virus and which bears powerful
promoter sequences which will bind host cell
transcription factors and allow high level expression of
the transferred cDNA.
Both the art and science of gene transfer revolve
around which vectors to use and how to get them into
the cells of interest. In gene therapy it is important that
the vector must not cause adverse effects such as
immune or inflammatory reactions, expression in the
wrong tissue, or, worse, spread to other people.
Inhibiting gene expression may also be
therapeutic
Techniques designed to transfer cDNA constructs into
cells can also be exploited to interfere with gene
expression by administering antisense oligonucle›
otides (fig 4). These consist of 20 or so nucleotides syn›
thesised in a sequence which complements the mRNA
of interest. The oligonucleotides bind the mRNA and
prevent translation of the protein. Antisense oligonu›
cleotides can be administered in vivo and have great
promise in treating disorders of cell proliferation. For
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Fig 2 Principles of gene transfer. cDNA for a protein foreign to the host cell is
incorporated into a DNA vector, which is then introduced or “transfected” into cells. The
cDNA will be transiently expressed before being eliminated. However, occasionally vector
DNA incorporates into cellular DNA, and these stably transfected cells can be selected in
experimental settings
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Fig 3 Control of gene expression. Transcription of DNA by a
multiprotein complex with RNA polymerase activity is regulated by
binding transcription factor proteins just upstream (or 5’) of the
open reading frame of the gene. RNA arising from introns is
spliced out to yield mature mRNA which arises from the exons of
the gene by means of the “cut and paste” process shown. The
capacity of mRNA to be translated by ribosomes can be regulated
by RNA sequences in the 3’ untranslated region downstream of the
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example, the fibrocellular intimal hyperplasia underly›
ing restenosis of atheromatous vessels after successful
angioplasty can be blocked by antisense to the gene
c›myb, which encodes a nuclear protein essential for cell
division. However, because antisense strategies don’t
always work there is growing interest in using
ribozymes, enzymes which specifically recognise and
degrade particular mRNAs. Although antisense
strategies might lack the glamour of gene therapy, the
ability selectively to turn off gene expression may prove
particularly important in medicine.
Knockout and transgenic technologies
Perhaps the best test of a gene function is provided by
manipulating the genome of experimental animals.
This is easiest in mice because scientists can now
culture undifferentiated but pluripotential murine
embryonic stem cells. Genetically altered embryonic
stem cells can be microinjected into early embryos so
that the manipulated cells contribute to all cell types of
the resulting chimera, including germ line cells. Breed›
ing these “founder” mice produces individuals carrying
one copy of the altered gene and one normal copy
(heterozygotes) or mice carrying two altered copies
(homozygotes).
This technique has proved particularly useful in
generating models of disease in which there is a genetic
“loss of function.” So called knockout mice are created
by means of homologous recombination and targeted
mutagenesis, techniques by which the gene of interest is
inactivated by swapping the normal DNA for a similar
DNA construct with a mutation. The DNA “plugged in”
to the embryonic stem cell genome also contains a
selection element such as a neomycin resistance gene so
that cells bearing the desired mutation can be selected
prior to injection into embryos because the knockout
cells can propagate in otherwise toxic neomycin.
Knockout mice can also be used to model the con›
sequences of somatic mutations which arise after birth
and are believed to be particularly important in
carcinogenesis. Mice deficient in the tumour suppres›
sor gene p53 in the germ line are models of human
Li›Fraumeni syndrome, developing multiple tumours
because of defects in deletion of cells in which ionising
radiation causes somatic mutations which activate
tumour promoting genes. Indeed, somatic mutations
inactivating p53 contribute to the pathogenesis of
about a third of tumours. It will soon be possible to
model such mutations by exploiting new techniques
that allow you to switch on gene inactivation in
particular cell lineages at will.
Transgenic technology, in which a normal gene is
overexpressed for investigative purposes, preceded
embryonic stem cell techniques and can be used in ani›
mals other than mice. However, transgenesis without
embryonic stem cells is much more hit and miss
because it relies on chance incorporation of DNA
injected into early embryos. Nevertheless, the technique
works, and the most dramatic practical application of
transgenesis may prove to be in xenografts—transplants
from animals to man. Normally, pig kidneys are
rejected rapidly by primates because the recipient has
high titres of antibodies which react with the glycopro›
teins on the surface of pig cells, especially endothelial
cells lining the vasculature of the graft. Antibody
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Synthetic antisense oligonucleotide binds
complementary mRNA sequence, preventing translation
Fig 4 An antisense oligonucleotide prevents translation of an
mRNA
Glossary
Allele—One of two or more alternative forms of a gene
which occupy the same locus (position) on a particular
chromosome. Homozygotes bear identical alleles at
two corresponding loci on a pair of chromosomes;
heterozygotes have two different alleles.
Complementary DNA (cDNA)—A DNA copy made from
a messenger RNA template which is transcribed in a
“finish to start” orientation by a reverse transcriptase
enzyme. When the cDNA is transcribed in the
conventional orientation by an ordinary RNA
polymerase enzyme a copy of the parent mRNA is
produced. Consequently, cDNAs are valuable when
one wants to mimic endogenous expression of a gene.
DNA construct—An engineered piece of DNA, usually
designed for incorporation into a viral based vector for
expression in other cells. For example, a construct
might incorporate a deliberately mutated cDNA such
that an abnormal form of the corresponding protein is
ultimately produced.
Homologous recombination—Exchange of chromosomal
DNA, by recombination or “crossing over” for another
stretch of DNA which is homologous or similar.
However, in gene manipulation experiments the
replacement DNA has been subtly altered to affect the
properties of the transcribed/translated product.
Positional cloning—Aims to identify the locus and the
gene responsible for a particular disorder/protein
relative to mapped markers, usually microsatellites.
This is determined by linkage analysis which assesses
the frequency with which a particular marker
cosegregates with the disorder/protein in families.
Because there may be crossing over of DNA between a
pair of chromosomes the further a gene is from a
marker the lower the chance of cosegregation. Cloning
involves sequencing the gene in its entirety, usually in
overlapping segments.
Targeted mutagenesis—A powerful technique in which
particular bases in DNA are deliberately mutated to
alter the properties of the mRNA resulting from DNA
transcription by RNA polymerase. In turn this can
alter the amino acids in the encoded protein, truncate
the protein, or prevent protein expression altogether.
Transcription factors—Proteins which bind “promoter”
regions of DNA upstream of the sequences which
encode mRNA, thereby leading to assembly of an
RNA polymerase and transcription of the gene.
Yeast artificial chromosomes (YACs)—Can accommodate
long stretches of foreign DNA and act as storage
vessels which can be propagated in yeast cells in
culture.
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fixation leads to complement activation, endothelial
injury, thrombosis, and graft loss—so called hyperacute
rejection. However, these phenomena are suppressed if
the transplanted pig tissue overexpresses human cell
surface proteins that regulate the activation of the com›
plement system. Therefore pigs transgenic for comple›
ment regulatory proteins could be used as a source of
organs for human transplantation. Nevertheless, apart
from ethical and safety considerations, xenografts may
prove susceptible to long term immunological injury by
T cells rather than complement.
Molecular microbiology
Lastly, genetic approaches are proving important in
infectious and parasitic diseases. By applying modern
molecular genetic techniques to the study of microbial
pathogenicity and to host resistance susceptibility, new
insights are being gained into treatment and
prevention, by vaccination and other strategies. For
example, the particularly challenging problem of
severe malaria due to Plasmodium falciparum, which
resists both treatment and attempts at prevention by
vaccination, is being addressed by a two pronged
genetic approach. Firstly, a yeast artificial chromosome
and expressed sequence tag map (see above) of the P
falciparum genome is being constructed to speed up
molecular analyses of potential targets in the parasite
for treatment and vaccines. Secondly, attempts are
being made to identify human genes which determine
deleterious or advantageous responses to infection.
Together these approaches could yield new vaccine
candidates and new treatments.
Conclusions
The potential power of genetic approaches to disease
is already great. My next article will deal with the
rapidly evolving discipline of molecular cell biology.
The tools described above are being used to investigate
many different disorders. Furthermore, the importance
of genetic approaches may redouble with the
anticipated success of the human genome project.
Watch this space.
Lesson of the week
Man’s best friend: life threatening sepsis after minor
dog bite
D J Mellor, Sunil Bhandari, K Kerr, A R Bodenham
Minor bites from domestic pets are common, usually
causing no more than a superficial lesion. In an Ameri›
can series, however,1 animal bites were the presenting
complaint in about 1% of all referrals to emergency
rooms. Although severe bite injuries usually present
early, for management of soft tissue injury as well as
prophylaxis against tetanus and rabies infection,
apparently trivial injuries may present later due to
insidiously developing, local or systemic infection.
Catastrophic sepsis following late presentation after
apparently trivial animal bites has been described
before.2 3 We describe a case of cardiovascular collapse,
purpura fulminans, and acute renal failure in response
to infection with capnocytophaga after an apparently
trivial bite from a dog.
Case report
A 55 year old man who had been in good health was
admitted to hospital with a 36 hour history of fever,
rash, diarrhoea, and vomiting. Four days earlier he had
been bitten by his pet dog. This hand wound apparently
required no medical attention and did not look infected
at any time. The history of his bite became apparent
only retrospectively four days after admission, when the
results of blood culture became available.
On admission he had an oral temperature of 39°C.
Examination showed a widespread purpuric rash and
poor peripheral perfusion. His blood pressure was
90/40 mm Hg and his pulse rate was 130 beats/minute.
He was confused. Arterial blood gas concentrations
showed a compensated metabolic acidosis with a pH of
7.38, a partial pressure of carbon of 2.6 kPa, a partial
pressure of oxygen of 10.1 kPa, and a bicarbonate con›
centration of 11 mmol/l while he was breathing room
air. His haemoglobin concentration was 131 g/l with a
white cell count of 6.7×109/l. In support of the clinical
signs, a haematological profile confirmed a picture of
disseminated intravascular coagulation with a platelet
count of 9×109/l and a prothrombin time of 36 s (nor›
mal 13 s), reduced fibrinogen concentration (0.002 g/l),
and increased concentrations of fibrin degradation
products ( > 0.016 g/l). The combination of purpuric
rash and multiple organ system involvement in an acute
septic process led to the provisional diagnosis of
meningococcal septicaemia. After a full sepsis screen,
including blood cultures, he received 1 g of intravenous
cefotaxime.
Despite initial treatment his condition continued to
deteriorate, and he required intensive care and
mechanical ventilation owing to deteriorating gas
exchange. Haemofiltration and haemodialysis were
needed for oliguric acute renal failure (creatinine con›
centration 653 ìmol/l, urea concentration 26 mmol/l),
and he received inotropic support (adrenaline and
dopexamine) for his circulation. His disseminated
intravascular coagulation was supported with transfu›
sions of platelets, fresh frozen plasma, and cryoprecipi›
tate, as required. Benzyl penicillin and metronidazole
were added to the cefotaxime antibiotic regimen.
Four days after admission, a Gram negative bacillus
was detected in his initial blood cultures. This was later
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shown to be Capnocytophaga canimorsus. He was
discharged from the intensive care unit one month
later. His (presumed) acute tubular necrosis had
completely resolved. He underwent considerable
peripheral amputation owing to ischaemic gangrene
(fig 1), but subsequent reconstructive surgery to his feet
allowed him to maintain independent mobility, and he
was in good health one year later.
Discussion
Capnocytophaga spp are commensal bacteria in the
mouths of dogs and cats.2 Infection has been reported
after bites from cats and dogs, but such catastrophic
infection in previously healthy people is rare. Case
reports suggest a higher risk in patients immunocom›
promised by haematological malignancy,4 splenectomy,5
or cirrhosis.6
Capnocytophaga spp are fastidious, capnophilic
Gram negative rods. Growth in blood cultures is slow
and a rapid provisional diagnosis may be made by
Gram staining buffy coat preparations or material
obtained from petechial lesions. Of the different
species of Capnocytophaga, C canimorsus (formerly Cen›
tre for Disease Classification Dysgonic Fermentor›2
(CDC DF›2)) is the most sinister, with a high mortality.
Like other common animal and human oral commen›
sals responsible for infection from bites, Pasteurella spp,
Staphylococcus aureus, and anaerobic organisms, Capno›
cytophaga spp are susceptible to co›amoxiclav as well as
â›lactam antibiotics, erythromycin, chloramphenicol,
and tetracycline.7
The management of bite injuries has been
reviewed and the role of prophylactic antibiotics
questioned.8
Our case suggests that no animal bite can be
regarded as innocuous prospectively. The true cause of
our patients’ illnesses became clear only after capnocy›
tophaga had been isolated from blood cultures, outlin›
ing the importance of taking an adequate history in
these circumstances. The case shows the need for
rigorous wound toilet and appropriate antibiotic
prophylaxis to all animal bites regardless of extent.
1 Wiggins ME, Akelman E, Weiss AP. The management of dog bites and
dog bite infections to the hand. Orthopedics 1994; 17:617›23.
2 Westwell AJ, Spencer MB, Kerr KG. DF›2 bacteraemia following cat bites.
Am J Med 1987; 83: 1170.
3 Hantson P, Gautier PE, Vekemans MC, Fievez P, Evrard P, Wauters G, et al.
Fatal Capnocytophaga canimorsus septicaemia in a previously healthy
woman. Annals of Emergency Medicine 1991; 20:93›4.
4 Ndon JA. Capnocytophaga canimorsus septicaemia caused by a dog bite
in a hairy cell leukaemia patient. J Clin Microbiol 1992; 30:211›3.
5 Dire DJ, Hogan DE, Riggs MW. A prospective evaluation of risk factors for
infections from dog›bite wounds. Academic Emergency Medicine
1994;1:258›66.
6 Roblot P, Bazillou M, Grollier G, Becq›Giraudon B, Fauchere JL.
Septicaemia due to Capnocytophaga canimorsus after a dog bite in a cir›
rhotic patient. Eur J Clin Microbiol Infect Dis 1993; 12:302›3.
7 Krol›van Straaten MJ, Landheer JE, de Maat CEM. Capnocytophaga
canimorsus (formerly DF›2) infections: review of the literature. Neth J Med
1990; 36:304›9.
8 Callaham M. Prophylactic antibiotics in dog bite wounds: nipping at the
heels of progress. Annals of Emergency Medicine 1994; 23:577›9.
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Comparing treatments
As the enuresis clinic wore on the avuncular paediatrician gave a
reasoned opinion of its value to the two attendant medical students.
He considered the changing fashions of his specialty and was
equanimous that none of his colleagues would continue the clinic
after his impending retirement.
A mother brought in her two sons. The younger was returning his
enuresis alarm. Now dry at night, the boy demonstrated his star chart,
complete in its latter stages. The alarm was redundant, the management
strategy successful, and both mother and child were grateful. The lesson
to the medical students was reinforced with cautionary examples of the
adverse effects of tricyclic antidepressant drugs when prescribed to treat
nocturnal enuresis, and their mortality in accidental overdose.
As the family rose to leave the paediatrician asked if the elder boy
had suffered from enuresis. “Much worse than his brother” was the
reply. “Did he use the alarm too?” asked the paediatrician. “Yes, we
tried everything. Then one morning he wet the sheets when I’d no
clean linen, it was pouring rain, and I was exhausted with the baby. I
burst into tears, and before I knew it, I’d put him across my knee and
given him a right good hiding. He never wet the bed again.”
One condition and three treatments. The alarm may be overtaken
by the natural history of the condition, the drugs are potentially lethal
and the anecdotal report of the mother’s effective treatment is difficult
to reproduce and impossible to advocate. How much else in modern
clinical practice is valiant but misguided, useless or harmful? What
clinical condition does not have current treatments that are ineffective,
dangerous, or both? Useful variables to compare treatments are
difficult to find. We often measure what is easy to measure. Blood
pressure and pulse are recorded when we would rather know cardiac
output and tissue perfusion.
For enuresis, soaked sheets and pyjama trousers are obvious
criteria to observe. Our 3 year old daughter is indignant when we
confuse bed wetting with what she insists is unrelated and profuse
sweating. When comparing treatments, if your seemingly suitable
endpoint, easy to define and detect, is discovered to have multiple
causes you are far from home and dry.
David Duthie is a consultant anaesthetist in Cambridge
Fig 1 Peripheral ischaemic gangrene secondary to capnocytophaga
septicaemia
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